SavedAdd your journal

Journals / Genel Tıp Dergisi / 2013 / Cilt: 23 - Sayı: 3

Parvovirus B19

HATİCE TÜRK DAĞI
Pages
96–102
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

There is no specific antiviral therapy, the treatment is symptomatic

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Parvovirus B19 is a small DNA virus belongs to Erytrovirus genus of Parvoviridae family.
📊
Key Findings & Data:Three genotypes of the virus which have approximately 13-14% nucleotide sequence differences are defined.
💡
Conclusion & Impact:There is no specific antiviral therapy, the treatment is symptomatic
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Parvovirus B19 is a small DNA virus belongs to Erytrovirus genus of Parvoviridae family. Three genotypes of the virus which have approximately 13-14% nucleotide sequence differences are defined. Genotype 1 and 2 are common in Europe and the United States while genotype 3 is limited to sub-Saharan Africa and South America. Parvovirus B19 is transmitted by mainly respiratory tract sec- retions, blood transfusion, organ transplantation and transplacental route. Parvovirus B19, a causative agent of erythema infectiosum which is an eruptive diseases of childhood, causes arthropathies in adults, aplastic crisis especially in patients with chronic hemolytic anemia. Hydrops fetalis and congenital anemia may develop in a fetus as a concequence of an infection in a pregnant woman with B19 virus. Spesific etiologic diagnosis of infection can be made by serological tests or detection of viral nucleic acid by polymerase chain reaction. Although there are vaccine candiadates shown to be safe and efficacious in clinical trials, none of them is approved currently for use. There is no specific antiviral therapy, the treatment is symptomatic

Özet

Parvovirus B19, Parvoviridae familyasının Erytrovirus genusunda yer alan küçük bir DNA virusudur. Virusun yaklaşık olarak %13- 14 oranında farklı nükleotid sekansa sahip üç genotipi tanımlanmıştır. Genotip 3 sahra-altı Afrika ve Güney Amerika ile sınırlı iken genotip 1 ve 2, Avrupa ve ABD'de yaygındır. Parvovirus B19, solunum yolu sekresyonları başta olmak üzere kan transfüzyonu, organ nakli ve transplasental yol ile bulaşmaktadır. Çocukluk çağının döküntülü hastalıklarından eritema infeksiyozumun etkeni olan par- vovirus B19, erişkinlerde artropatilere, özellikle kronik hemolitik anemisi olan hastalarda aplastik krize neden olmaktadır. Hamile bir kadının B19 virusu ile enfekte olması sonucunda, fetüste hidrops fetalis ve konjenital anemi gelişebilmektedir. Enfeksiyonun özgül etiyolojik tanısı serolojik testlerle ve polimeraz zincir reaksiyonu yöntemi kullanılarak viral nükleik asidin belirlenmesi ile yapılabilir. Klinik çalışmalarla güvenli ve etkili olduğu gösterilen aşı adayları olmasına rağmen hiçbiri kullanım için onaylanmamıştır. Virusa özgül antiviral tedavi yoktur, semptomatik tedavi uygulanmaktadır

🔖

Cite This Article

DAĞI, H. T. (2013). Parvovirus B19. Genel Tıp Dergisi, Cilt: 23 - Sayı: 3, 96–102. https://ajindex.com/articles/224850

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Cossart YE, Field AM, Cant B, Widdows D. Parvovirus-like partic- les in human sera. Lancet 1975;1:72-3.
  2. Allander T, Tammi MT, Eriksson M, et al. Cloning of a human par- vovirus by molecular screening of respiratory tract samples. Proc Natl Acad Sci U S A 2005;102:12891-6.
  3. Jones MS, Kapoor A, Lukashov VV, et al. New DNA viruses iden- tified in patients with acute viral infection syndrome. J Virol 2005;79:8230-6.
  4. Anderson MJ, Jones SE, Fisher-Hoch SP, et al. Human parvovi- rus, the cause of erythema infectiosum (fifth disease)? Lancet 1983;1:1378. White DG, Woolf AD, Mortimer PP, et al. Human parvovirus arth- ropathy. Lancet 1985;1:419-21.
  5. Pattison JR, Jones SE, Hodgson J, et al. Parvovirus infections and hypoplastic crisis in sickle-cell anaemia. Lancet 1981;1:664-5.
  6. Brown T, Anand A, Ritchie LD, et al. Intrauterine parvovirus infec- tion associated with hydrops fetalis. Lancet 1984;2:1033-4. Anderson LJ. Human Parvovirus B19. In: Richman DD, Whitley RJ, Hayden FG, editors. Clinical Virology. 2th ed. Washington: ASM Press 2002;28:597-607.
  7. Sharp CP, LeBreton M, Kantola K, et al. Widespread infection with homologues of human parvoviruses B19, PARV4, and hu- man bocavirus of chimpanzees and gorillas in the wild. J Virol 2010;84:10289-96.
  8. Murray PR, Rosenthal KS, Pfaller MA. Medical Microbiology. 5th ed. Philadelphia: Elsevier Mosby:2005;56:573-7. Portmore AC. Parvoviruses (erythema infectiosum, aplastic crisis). In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases. 4th ed. New York: Churchill Livingstone 1995:1439-46.
  9. White DO, Fener FJ. Parvoviridae. Medikal Viroloji. (Çeviri: Doy- maz MZ) İstanbul: Nobel Tıp Kitabevleri 2000;17:285-93.
  10. Jones LP, Erdman DD, Anderson LJ. Prevalence of antibodies to human Parvovirus B19 nonstructural protein in persons with various clinical outcomes following B19 infection. J Infect Dis 1999;180:500-4.
  11. Anderson MJ, Higgins PG, Davis LR, et al. Experimental parvovi- ral infection in humans. J Infect Dis 1985;152:257-65. Jordan JA. Human Parvoviruses. In: Murray PR, Baron EJ, Jorgen- sen JH, Landry ML, Pfaller MA editors. Manual of Clinical Micro- biology. 9th ed. (Çeviri ed: Başustaoğlu A) Ankara: Atlas Kitapçılık 2009:1622-30.
  12. Ergaz Z, Ornoy A. Parvovirus B19 in pregnancy. Reproduc Toxicol 2006;21:421-35.
  13. Barlaw GD, McKendrick MW. Parvovirus B19 causing leucopenia and neutropenia in a healthy adult. J Infect 2000;40:192-5.
  14. Wan Z, Zhi N, Wong S, Keyvanfar K,